Consensus $136.43M. The company ended December 31, 2024 with cash, cash equivalents, marketable securities and restricted cash of approximately $292M. The company used approximately $32M of cash in the twelve months ended December 31, 2024. The company said, “The Company’s unaudited, preliminary 2024 financial results are based on current expectations and do not represent a comprehensive statement of the Company’s financial results for the fourth quarter or full year 2024. These unaudited, preliminary results remain subject to the completion of financial closing procedures, internal reviews, and annual audit procedures.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix reports preliminary Q4 revenue $34.9M, consensus $34.35M
- Quanterix price target lowered to $11 from $15 at TD Cowen
- Quanterix Announces Merger with Akoya Biosciences
- Quanterix Merges with Akoya for Enhanced Biomarker Solutions
- Quanterix to acquire Akoya Biosciences in an all-stock transaction